FIELD: medicine, oncology, gastroenterology, immunobiotechnology.
SUBSTANCE: invention describes an antibody or its derivative, or its fragment showing the structure able to bind the target structure. Antibody is located inside and on surface of human gastroenteric tract epithelial tumor cells and in subpopulation of normal gastroenteric tract epithelial cells. Indicated binding structures comprise sequences determining the complementarity of the region (CDR) in light chain comprising in main amino acids at number 23-33 (CDR 1), 49-55 (CDR 2), 88-98 (CDR 3) of amino acid sequence represented in SEQ ID NO:2, and CDR sequence in heavy chains comprising in main amino acids at number 158-162 (CDR 1), 177-193 (CDR 2), 226-238 (CDR 3) of amino acid sequence represented in SEQ ID NO:2, or other binding structures with similar unique binding properties. Also, invention describes the target-structure located inside or on surface of tumor cells: vaccine composition designated for treatment of malignant disease in human and comprising abovementioned antibody. Also, invention describes methods for treatment and diagnosis of malignant disease. Using this invention provides preparing antibodies that relieve identification of new phenotype-specific tumor-associated antigens, to predict and treat metastatic human diseases. Invention can be used in medicinal practice.
EFFECT: valuable medicinal properties of antibodies.
37 cl, 21 dwg, 4 tbl, 8 ex
Title | Year | Author | Number |
---|---|---|---|
NEW ANTIBODY SHOWING SPECIFICITY TO MALIGNANT LARGE INTESTINE TUMOR | 2001 |
|
RU2268068C2 |
CONJUGATE ELICITING ABILITY TO ACTIVATE IMMUNE SYSTEM AND PHARMACEUTICAL COMPOSITION COMPRISING INDICATED CONJUGATE | 1997 |
|
RU2198895C2 |
CONJUGATE TO STIMULATE IMMUNE RESPONSE AGAINST A TARGET CELL, METHOD TO TREAT MALIGNANT TUMORS IN MAMMALIANS | 1995 |
|
RU2183215C2 |
BIOLOGICAL MATERIALS AND APPLICATION THEREOF | 2006 |
|
RU2432363C9 |
HUMANIZED ANTI-VEGF MONOCLONAL ANTIBODY | 2020 |
|
RU2809746C2 |
NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
CANCER-MODIFYING ANTIBODIES | 2008 |
|
RU2468036C2 |
USE OF CD 151 ANTIBODIES FOR TREATING CANCER | 2007 |
|
RU2464041C2 |
SELECTIVE BIFUNCTIONAL DRUG ON THE BASIS OF FRAGMENTS OF CAMEL SINGLE-CHAIN ANTIBODIES, AIMED ON TUMOR RECEPTORS CD47/CD44, INTENDED FOR THERAPY OF MALIGNANT NEOPLASMS | 2016 |
|
RU2658764C1 |
INHIBITION OF TUMOUR METASTASES BY ANTIBODIES AGAINST NEUROPILINE-2 | 2007 |
|
RU2437677C2 |
Authors
Dates
2005-12-20—Published
2000-10-26—Filed